The biopharma industry is witnessing a surge in investment in the immunology field, with over 10 buyouts of immunology and inflammation (I&I) drug developers this year. Several biotech companies have raised impressive funds to advance the development of their immunology-related research and development (R&D). These companies are working on innovative treatments for various diseases, including…
